Biohaven grants Ono Pharma regional rights to BHV-1300 and extracellular IgG degrader programmes

Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines.

Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.

Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion.

STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

The European Commission has authorised Icotyde for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

Henlius has received approval in Pakistan for HANDAYUAN, its adalimumab biosimilar, marking the product's first regulatory approval outside China.

Average annual compensation for US allergy and immunology physicians reached $335,978 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for specialists working in allergy and immunology.

Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.

The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders.